Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia

Blood

Volumn 118, Issue 9, 2011, Pages 2618-2621

  Eapen, Mary ^a   Le Rademacher, Jennifer ^a   Antin, Joseph H ^b   Champlin, Richard E ^c   Carreras, Jeanette ^a   Fay, Joseph ^d   Passweg, Jakob R ^e   Tolar, Jakub ^f   Horowitz, Mary M ^a   Marsh, Judith C W ^g   Deeg, H Joachim ^h  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF BASEL   (Switzerland)

^f UNIVERSITY OF MINNESOTA   (United States)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN;

ADOLESCENT; ADULT; AGED; APLASTIC ANEMIA; ARTICLE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; COMPARATIVE STUDY; DONOR SITE; FEMALE; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HLA MATCHING; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 80052406910     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-05-354001     Document Type: Article

References (14)

1. Young N.S., Calado R.T., Scheinburg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108(8):2509-2519.
2. Rosenfeld S., Follman D., Nunez O., Young N.S. Antithymocyte globulin and cyclosporine for severe aplastic anemia. JAMA. 2003;289(9):1130-1135.
3. Marsh J.C.W., Ball S.E., Cavenagh J., et al. Guidelines for the diagnosis and management of aplastic anemia. Br J Haematol. 2009;147(1):43-70.
4. World Marrow Donor Association Donor Registries Working Group. Stem Cell Donor Registries Annual Report 2008 (12th ed). Leiden, The Netherlands: World Marrow Donor Association; 2008
5. Schrezenmeier H., Passweg J.R., Marsh J.C., et al. Worse outcomes and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood. 2007;110(4):1397-1400. (Pubitemid 47281442)
6. Bacigalupo A., Socie G., Schrezenmeier H., et al. Matched sibling transplants for aplastic anemia: Survival advantage for marrow vs peripheral blood transplants in all age groups [abstract]. Blood. 2010;116:523a
7. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825-828.
8. Flowers M.E., Kansu E., Sullivan K.M. Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am. 1999;13(5):1091-1112. (Pubitemid 29489294)
9. Klein J.P., Moeschberger M.L. Survival Analysis: Techniques of Censored and Truncated Data (2nd ed). New York, NY: Springer Verlag, 2003.
10. Cox D.R. Regression models and life tables. J R Stat Soc B. 1972;34(2):187-220.
11. Margolis D.A., Casper J.T. Alternative donor transplantation for severe aplastic anemia. Semin Hematol. 2000;37(1):43-55. (Pubitemid 30080246)
12. Socie G., Henry-Amar M., Bacigalupo A., et al. Malignant tumors occurring after treatment of aplastic anemia. N Engl J Med. 1993;329(16):1152-1157. (Pubitemid 23295457)
13. Deeg H.J., Socie G., Schoch G., et al. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: A joint Seattle and Paris analysis of results in 700 patients. Blood. 1996;87(1):386-392. (Pubitemid 26011854)
14. Deeg H.J., O'Donnell M., Tolar J., et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood. 2006;108(5):1485-1491. (Pubitemid 44316112)